De Vries J P P M, Karimi A, Fioole B, Van Leersum M, Werson D A B, Van Den Heuvel D A F
Department of Vascular Surgery, St. Antonius Hospital, Nieuwegein, The Netherlands.
J Cardiovasc Surg (Torino). 2013 Jun;54(3):327-32.
The use of drug-eluting balloons for treatment of long-segment femoropopliteal artery obstructions has become widespread in recent years. The possibility to deliver a drug into the arterial wall with sustained antiproliferative effects, without leaving behind metal scaffolding, seems very promising. The current generation of drug-eluting balloons differs in the formulation of the drug (usually paclitaxel), technique of coating, and the elution excipients. Results of published randomized trials are reviewed in this report. A new innovative coating technique has been introduced recently. The PRIMUS® coronary drug-eluting balloon and the Legflow® peripheral drug-eluting balloon consist of paclitaxel nanoparticles that are embedded underneath the surface of the balloon as well as inside a new shellolic acid drug-release matrix. Risk for dislodgement of the paclitaxel particles is minimized in the newest generation of drug-eluting balloons. Short-term in vitro and in vivo results of this stable, coated balloon are promising, and large randomized trials have been started recently to gather more long-term and robust clinical data.
近年来，药物洗脱球囊用于治疗长段股腘动脉阻塞已变得十分普遍。在不遗留金属支架的情况下，将具有持续抗增殖作用的药物输送至动脉壁的可能性似乎很有前景。当前一代的药物洗脱球囊在药物配方（通常为紫杉醇）、涂层技术和洗脱辅料方面存在差异。本报告对已发表的随机试验结果进行了综述。最近引入了一种新的创新涂层技术。PRIMUS®冠状动脉药物洗脱球囊和Legflow®外周药物洗脱球囊由嵌入球囊表面下方以及新型虫胶酸药物释放基质内部的紫杉醇纳米颗粒组成。在最新一代的药物洗脱球囊中，紫杉醇颗粒脱落的风险降至最低。这种稳定的涂层球囊的短期体外和体内结果很有前景，最近已启动大型随机试验以收集更多长期且可靠的临床数据。
